10:16 AM EST, 11/10/2025 (MT Newswires) -- Personalis ( PSNL ) said Monday it obtained Medicare coverage of its NeXT Personal test for surveillance of cancer recurrence in breast cancer patients.

Medicare beneficiaries with stage 2 and 3 breast cancer will have coverage for recurrence monitoring with the test for up to six years, the company said.

Personalis ( PSNL ) shares were up more than 35% in recent trading.

Price: 9.38, Change: +2.45, Percent Change: +35.31